Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

Tesamorelin Dosing Protocol: 20 mg Vial — 10-Day Supply at 2

Tesamorelin 20 mg vial: 2 mg/mL, 2 mg/day (100 units). 10 days per vial. Most efficient for full 26-week protocol. Reviewed Feb 2026. Reviewed Feb 2026.

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

Tesamorelin Dosing Protocol: 20 mg Vial — 10-Day Supply Guide

High-volume tesamorelin supply from the 20 mg vial — provides 10 daily doses at the FDA-approved 2 mg/day rate, minimizing reconstitution frequency.

Quickstart highlights

Tesamorelin at 2 mg/day over 26 weeks produces the highest-evidence visceral fat reduction of any GHRH analogue (15.2% in Phase 3, NCT00311948 / Falutz 2010).

Concentration: 2 mg/mL (20 mg vial + 10 mL bacteriostatic water).

At 2 mg/mL: 2 mg = 100 units (1 mL) once daily — FDA-approved Egrifta SV dose.

One 20 mg vial provides exactly 10 daily doses at 2 mg; reconstitute every 10 days.

Phase 3 (NCT00311948): 2 mg/day x 26 weeks — 15.2% visceral fat reduction vs. 0.7% placebo.

Requires 10 mL bac water per reconstitution — use a 10 mL syringe or four 2.5 mL additions.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

1-4

1000

50

Once daily

1 mg — 50 units; 20 vial provides 20 doses at this level (20 days)

5-26

2000

100

2 mg — 100 units (FDA-approved dose); 20 mg vial provides 10 daily doses (10 days per reconstitution)

Your free Tesamorelin tracker

Dose reminders

Injection logging

Cycle progress

Reconstitution steps

Draw 10 mL bacteriostatic water (use four 2.5 mL draws from a 3 mL syringe, or a 10 mL syringe) into the vial.

Inject slowly down the vial wall in divided portions to minimize foaming.

Swirl gently between additions; allow to fully dissolve before drawing doses.

Final concentration: 2 mg/mL (20 mg / 10 mL). Label with date; refrigerate at 2–8 °C. Use within 28 days.

Supplies needed

12-week plan

6 vials

84 syringes

60 mL bac water

84 alcohol swabs

26-week plan

19 vials

182 syringes

190 mL bac water

182 alcohol swabs

Protocol overview & cycle notes

Optimize 26-week tesamorelin protocol logistics by using the 20 mg vial — reducing reconstitution events to every 10 days versus every 2.5–5 days with smaller vials, improving sterility management and convenience.

Cycle length: 26 weeks on.

Off-cycle: 8 weeks off; measure IGF-1 and waist circumference before resuming.

Storage & handling

Injection & tracking tips

Reconstituting 20 mg requires 10 mL bac water — use a 10 mL syringe or four sequential 2.5 mL additions.

The 20 mg vial at 2 mg/day requires reconstitution every 10 days — reducing handling events to ~78 reconstitutions for a full 26-week protocol versus 182 with 5 mg vials.

Mark each dose draw on the vial label to track remaining volume.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

Measure waist circumference and weight weekly.

Check IGF-1 at baseline, 8 weeks, and 16 weeks.

Track fasting glucose and HbA1c every 8 weeks; GH elevation affects insulin sensitivity.

How this works & references

Sources

Metabolic effects of a growth hormone-releasing factor in patients with HIV. Falutz J et al. — N Engl J Med — 2007

FDA — Egrifta SV (tesamorelin) 2 mg/day prescribing information

Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. González-Sales M et al. — Clin Pharmacokinet — 2015

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Falutz J et al. — J Acquir Immune Defic Syndr — 2010

Frequently asked questions

Related protocols

KLOW Blend Dosing Protocol — BPC-157, TB-500, KPV & GHK-Cu Guide

KLOW peptide blend (BPC-157 + TB-500 + KPV + GHK-Cu) dosing guide for tissue repair, anti-inflammatory support, and extracellular matrix remodeling — the GLOW blend plus KPV.

GLOW Blend Dosing Protocol — BPC-157, TB-500 & GHK-Cu Skin & Repair Guide

GLOW peptide blend (BPC-157 + TB-500 + GHK-Cu) dosing guide for tissue repair, angiogenesis, and collagen and connective-tissue remodeling.

Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide

Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.

Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide

Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Need help?

Connected topics

Follow this recovery question